Treatment of Advanced or Metastatic Atypical Lung Carcinoid — Including High-Grade Presentations and Progression After Somatostatin Analogue Therapy
This protocol applies to patients with advanced or metastatic atypical lung carcinoid (AC), significantly progressive carcinoid, or disease that has progressed on somatostatin analogue (SSA) therapy — a distinct population requiring a structured, evidence-based approach.
Clinical scenario
The target population includes patients with advanced or metastatic atypical lung carcinoid — including high-grade presentations — as well as those with significantly progressive carcinoid or documented progression following somatostatin analogue therapy. Progression after SSA is an established threshold that defines escalation to further systemic management for both typical and atypical carcinoid subtypes.
Treatment approach — partial overview
Platinum-based chemotherapy is a central component of management for this population. The complete protocol covers agent selection, sequencing rationale, and decision criteria — all available via the link below.
References
- DOI: 10.1016/j.annonc.2021.01.003
- Everolimus is considered as first-line therapy in the majority of ACs or following progression to SSA for both TC and AC patients [II, B] (see Supplementary Material, available at https://doi.org/10.1016/j.annonc.2021.01.003 for detailed LUNA trial data).
- Among platinum-based agents, oxaliplatin-based ChT is recommended by the majority of the panel [IV, C].
View source ↗